80. COPD exacerbation

P555
Relationships between elevated cardiac troponin levels in COPD exacerbations and subsequent cardiac investigation and management
Padman R. Vamadevan, Andrew W. Hitchings, Dana Ahmood, Tejwant S. Grewal, Emma H. Baker. Clinical Pharmacology Unit, Division of Biomedical Sciences, St George’s, University of London, London, United Kingdom

Background: Admission cardiac troponins (cTn) are elevated in 18-27% patients with COPD exacerbations (BMC Pulm Med 2009;9:35). Clinicians often attribute this rise to co-existing inflammation, anaemia or renal impairment. However, elevated cTn is associated with a significantly increased 30-day post-admission mortality independently of these factors, and its presence indicates underlying myocardial injury. We determined proportions of patients undergoing cardiac investigation and receiving cardiac protective treatment following an exacerbation-related cardiac troponin 1 (cTn1) rise.

Methods: 237 COPD patients (127 male, 73±1±1yrs) admitted with exacerbations between July 2008-9, and with a measured cTn1 within 24h of admission were retrospectively identified. Clinical information was retrieved using the electronic patient record.

Results: Admission cTn1 was “undetectable” (U, <0.02μg/L) in 15%, “measurable” (M, 0.02-0.05μg/L) in 59% and “elevated” (E, >0.05μg/L) in 26% of patients.

<table>
<thead>
<tr>
<th>U</th>
<th>M</th>
<th>E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investigations within 3 months of admission</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Echocardiography</td>
<td>11%</td>
<td>18%</td>
</tr>
<tr>
<td>Cardiac Catheterisation</td>
<td>0%</td>
<td>1%</td>
</tr>
<tr>
<td>Discharge medication (n=205)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>40%</td>
<td>40%</td>
</tr>
<tr>
<td>β-blocker</td>
<td>7%</td>
<td>5%</td>
</tr>
<tr>
<td>Statin</td>
<td>33%</td>
<td>42%</td>
</tr>
<tr>
<td>ACE inhibitor</td>
<td>27%</td>
<td>26%</td>
</tr>
</tbody>
</table>

Conclusions: cTn1 elevation is not specific for coronary thrombosis, and rises in exacerbations may reflect demand ischaemia, direct cardiac damage, or myocardial strain. No guidelines exist regarding the optimal management of such patients. However, given their increased risk of early mortality, further cardiac investigation to reveal underlying mechanisms of cTn1 release may enable appropriate therapeutic targeting and improve outcomes.

P556
Comparison of multidimensional assessment systems with regard to risk prediction for exacerbations of COPD

Aim: Acute Exacerbations of COPD (AECOPD) are major concerns with regard to morbidity, mortality and economic burden. In this study, we compared the efficacy of 3 assessment systems for predicting AECOPD: BODE index (Body mass index, airway Obstruction, Dyspnea, Exercise capacity), DOSE index (Dyspnea, airway Obstruction, Smoking status, Exacerbations); and ADO index (Age, Dyspnea, airway Obstruction).

Participants and methods: The frequency of exacerbations (FE) for a 1-year period was retrospectively studied for 183 consecutive patients with COPD. Following parameters were used to compare the results: pulmonary function tests, 6-minute walking test, MMRC dyspnea scale, low-attenuation area (LAA%) on HRCT and FE.

Results: The study included 183 patients (M/F 170/13). The mean age and FEV1/predicted were 71.4 years and 55.7%, respectively. The mean annual exacerbation rate was 0.57 per patient-year. FE was significantly correlated with the following parameters: lower FEV1/predicted (p<0.001), lower DLCO/VA (p<0.021), shorter 6MWD (p<0.016), higher MMRC (p<0.001), higher DOSE index (p<0.001), higher ADO index (p<0.001), and larger LAA% (p<0.002). FE was significantly associated with prescribed long-term oxygen therapy (Odds ratio [OR] 4.17, p<0.001) and exacerbation rate for the previous year (OR 2.79, p<0.001). The area under the receiver-operator curve for predicting exacerbation during the 1-year follow-up was 0.65 for the BODE index, 0.64 for the ADO index, and 0.75 for the DOSE index.

Conclusions: The BODE index appears to be superior to the BODE and ADO indices in terms of predicting exacerbations of COPD.

P557
Relation of red blood cell distribution width with long-term survival in acute exacerbation of chronic obstructive pulmonary disease
Sedat Altin1, Ezkem C. Seyhan1, Sinem Sokculu1, Seda Tural1, Innan Tural2, Gulsum Güngörlü1, 1Chest Diseases, Yedikule Teaching Hospital for Chest Diseases and Thoracic Surgery, Istanbul, Turkey; 2Cardiology, Bagcılar Education and Research Hospital, Istanbul, Istanbul, Turkey

Background: Cardiovascular risk factors and cardiac comorbidities are frequent in COPD patients. Red blood cell distribution width (RDW), an automated measure of red blood cell size heterogeneity (eg, anisocytosis) that is largely overlooked, is a newly recognized risk marker in patients with established cardiovascular disease (CVD). RDW may reflect nutritional deficiencies, bone marrow dysfunction, or systemic inflammation. To study the long-term prognostic value of red blood cell distribution width (RDW) in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease and to compare the value of this measurement with haemoglobin levels and anaemia status.

Methods: During a 4-year period, we studied 149 consecutive patients (aged 61 years, 128 male) hospitalized with COPD. Demographic, clinical, echocardiographic, and laboratory characteristics were registered at discharge and patients were closely followed-up for 40 months (25–49).

Results: Median RDW was 14.6% (13.5–16.5) and was higher among decedents (P<0.001). RDW levels above the median were associated with a significantly lower survival rate on long-term follow-up. These levels were predictive of death in anaemic patients and especially in non-anaemic patients even after adjustment in the multivariable model.

Conclusion: In the acute exacerbation of COPD RDW levels at discharge were associated with a worse long-term outcome, regardless of haemoglobin levels and anaemia status.

P558
Mathematical arterialisation for monitoring during exacerbation
Ulla Møller Weinreich1, Beata Rychwicka-Kielek 1, Bjarne Andersen 1, Rajat K Shrestha1, Bente Kjær1, Brage Ryhlicka-Kielek 1, Bjørn Andersen1, Rana Bibi 1, Lene Birker-Smith 1, Jørgen Kjær2, Stephen Edward Rees 1. 1Pulmonary Medicine, Aalborg Hospital, Aalborg, Denmark; 2Clinical Biochemistry, Aalborg Hospital, Aalborg, Denmark; 3Health Science and Technology, Aalborg University, Aalborg, Denmark

Repeated arterial puncture for acid-base and oxygenation status is painful, but quite common in COPD patients admitted for periods of exacerbation. Recently, a method has been presented (Rees, S.E. et. al. Comput. Methods Programs Biomed. 2006;81:18-25) for mathematically transforming values in peripheral venous blood to arterial levels, potentially eliminating the need for painful arterial puncture. This method has been evaluated at a single time point in COPD patients (Rees, S.E. et. al. Eur J Appl Physiol 2010;108:485-94).

The aim of this study was to evaluate the method in patients during the whole period of admission to the hospital for exacerbation. Twenty patients were studied over an admission of on average 5 days, with an average of 3 arterial blood samples taken during this period. For each arterial sample a paired peripheral venous sample was taken and used to calculate arterial values. Values of pH and arterial PCO2, calculated by the method compared well with those measured with a mean and standard deviation of the difference (measured minus calculated) of 0.000±0.010 pH and ±0.03±0.026 lPa PCO2. Figure 1 illustrates the ability of the calculated values (squares, dashed) of arterial pH, PCO2 and PO2 to mirror measured clinical changes (open circles, solid) in a single patient studied on six consecutive days.

Conclusions: The method may be a useful tool to evaluate COPD patients during admission without the need for repeated arterial punctures.
**P598**

**Do exacerbation outcomes in the POET-COPD™ trial differ between regions?**

Maureen P.M. Rutter-van Molkken,1, Leonardo M. Fabrizi2, Klaus F. Rabé1, Harald Kögler1, Thomas Glaab1, Hendrik Schmidt4, Kai M. Beech2, Claus Vogelmeier2,1

1Department of Health Economics, Institute for Medical Technology Assessment (IMTA), Erasmus University, Rotterdam, Netherlands; 2Department of Medical and Surgical Specialties, University of Modena & Reggio Emilia, Modena, Italy; 3Department of Pneumology, Grosshadern Hospital, Munich, Germany; 4Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany; 5Department of Internal and Pulmonary Medicine, Insaft Respiratory Research Institute, Wiesbaden, Germany; 6Division for Pulmonary Diseases, Hospital of the Universities of Giessen and Marburg, Marburg, Germany

**Background:** Exacerbation outcomes in chronic obstructive pulmonary disease (COPD) trials may vary between geographical regions due to differences in aspects such as health systems, local treatment paradigms or climate. The randomized, double-blind, double-dummy, 1-year POET-COPD™ trial (n=7376) showed fewer moderate or severe exacerbations in the tiotropium (18 μg qd) vs salmeterol (50 μg bid) group.

**Aims and objectives:** To examine whether geographical region influenced exacerbation outcomes.

**Methods:** Important inclusion criteria were age ≥40 years, postbronchodilator forced expiratory volume in 1 s (FEV1) ≤70% predicted and ≥1 exacerbation in prior year. Countries (n=25) were grouped into four regions: Eastern Europe, Western Europe, Nordic and Mediterranean. Interaction analyses were performed for time to first exacerbation (primary endpoint) and annual exacerbation rate.

**Results:** 7376 patients were randomized and treated. Results are shown in the table.

<table>
<thead>
<tr>
<th>Region</th>
<th>N Tiotropium / salmeterol</th>
<th>Tiotropium vs salmeterol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eastern Europe</td>
<td>24/9 (2142)</td>
<td>0.87 (0.70–0.95)</td>
</tr>
<tr>
<td>Western Europe</td>
<td>925/256</td>
<td>0.83 (0.72–0.97)</td>
</tr>
<tr>
<td>Nordic</td>
<td>70/75</td>
<td>0.85 (0.51–2.9)</td>
</tr>
<tr>
<td>Mediterranean</td>
<td>263/256</td>
<td>0.94 (0.62–1.34)</td>
</tr>
</tbody>
</table>

Conclusion: Post-hoc subgroup analysis of the POET-COPD™ trial by geographical region suggests that the exacerbation benefits of tiotropium over salmeterol are independent of region. Funded by Boehringer Ingelheim/Pfizer

**P560**

**Effect of acute exacerbations on circulating thrombotic and fibrinolytic markers in COPD patients**

Riccardo Polosa1, Mario Malerba2, Alessandro Radaeli3, Jaymin Morjaria4, Raimondo Gullo1, Giuseppe Di Maria1

1Pneumology and Allergy Unit, Puerta del Mar University Hospital, Cadiz, Spain; 2Biomedical Engineering and Telemedicine Researching Group, University of Cadiz, Cadiz, Spain; 3Preventive Medicine and Public Health Area, University of Cadiz, Cadiz, Spain

**Introduction:** Patients with COPD are prone to clinical exacerbations which are associated with increased airway inflammation, a potent pro-thrombotic stimulus.

**Aim:** To investigate whether activation of the endothelial-coagulative system occurs in association with COPD exacerbation.

**Methods:** Surrogate markers of inflammation were collected: interleukin-6 (IL-6); endothelium damage: von Willebrand’s factor (vWF); clotting activation: D-dimer (D-D), and prothrombin fragment 1+2 (F1+2); fibrinolytic response: plasminogen activator inhibitor 1 (PAI-1), in COPD subjects during exacerbation.

**Results:** In 30 COPD subjects, IL-6, VWF, D-D and F1+2 levels were elevated during exacerbation and decreased significantly at clinically stable condition (IL-6, p<0.05; VWF, p<0.001; D-D, p<0.001; F1+2, p<0.001). PAI-1 levels did not change at exacerbation compared to clinically stable situations.

**Conclusion:** High age, male sex, more than two comorbidities, need for non-invasive ventilation, low vWF and low BMI were associated with increased mortality after hospitalisation for exacerbation.

**P562**

**Development of an automated questionnaire for the early detection of COPD exacerbations (AQCE)**

Antonio Leon1, Sonia Astorga1, Mario Crespi2, Daniel Sánchez3, Iracucalda Falichi4, Felipe Crespi2,4

1Pneumology and Allergy Unit, Puerta del Mar University Hospital, Cadiz, Spain; 2Biomedical Engineering and Telemedicine Researching Group, University of Cadiz, Cadiz, Spain; 3Preventive Medicine and Public Health Area, University of Cadiz, Cadiz, Spain

**Background and aim:** This work’s goal is developing a COPD exacerbation symptoms and prodromes-based questionnaire for the early detection of exacerbations at home by a device for telemonitoring.

**Methods:** AQCE was linguistically and medically checked for inconsistencies, resulting in 15 items: general health status (1), cough (1), phlegm (2), dyspnea (3), sleep conditions (2), cold-like symptoms (4), lung sounds (1) and coordination test (1). A group of 52 stable patients reporting having had at least one severe exacerbation event was selected. Questionnaire understanding degree was determined by two experts by semi-structured interviews and 5-point Likert scale questions. Reliability was conducted by test-retest over spirometry, clinical evaluation, the AQCE and the validated questionnaire Clinical COPD Questionnaire (CCQ) in a range of 15-30 days. Concordance was established by using the intraclass correlation coefficient (ICC), stability by the Wilcoxon signed-rank test and reliability by Cronbach’s alpha.

**Results:** Items showed a high degree of comprehension for 97.1% of sample. Comprehension concordance between patients and expert was 0.71 and between patients and expert 0.53. Mean ICC in the first session was 42.63% (SD 16.69) and in the second one 41.18% (SD 17.5). CCQ did not vary significantly in test-retest. Total score for AQCE and each item independently was confirmed to return similar values and these results did not show statistically significant differences in test-retests. Internal consistency was 0.7.

**Conclusions:** AQCE is comprehensible, reliable, stable and consistent for COPD patients.

AMICA project AAL Joint Programme AAL-2008-1-176

**Abstract printing supported by **Chiesi Visit Chiesi at Stand D.30
P563 Procalcitonin use in acute exacerbations of COPD

Thomas Medvecky, Mark Jackson. Department of Respiratory Medicine, The Princess Royal Hospital, Brighton and Sussex University Hospitals NHS Trust, Haywards Heath, Sussex, United Kingdom

Background: Acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) contribute to a rising number of hospital admissions in United Kingdom [1]. This study investigates the role of procalcitonin (PCT) assay in antibiotic prescribing in AE-COPD.

Methods: A prospective study of 30 patients admitted with acute exacerbation of COPD in Winter 2010. All patients were assessed with routine X-ray, bloods, CRP and Procalcitonin essays. Decisions to treat with antibiotics were made using clinical impression and a standard PCT protocol [2]. Antibiotic use was discouraged if initial PCT level <0.25 mcg or 80-90% fall of peak PCT value after 72 hours. Primary outcomes measured in antibiotic use, length of stay, readmission rate.

Results: From 30 cases in our study 7/30 (23%) had antibiotics stopped on admission with PCT <0.25 mcg. 3/30 (10%) had antibiotics stopped after 72 hours PCT level fall. 13/30 (44%) had antibiotics irrespective PCT value and 7/30 (23%) did not need antibiotics clinically disregarding PCT use. Length of stay using PCT was 26% shorter vs no PCT use. No significant difference in re-admission rates (1/10 in PCT vs 2/20 no PCT use). The economical savings (stay,antibiotics) using PCT was 900 £/p.

Discussion: Procalcitonin significantly reduced the use of antibiotics in acute exacerbation of COPD. This means reduction in stay, antibiotic side effects, savings without increase rate in readmissions. Our data suggests the use of the PCT essay may improve clinical care in exacerbations of COPD. Further studies on a larger number of patients are needed.

References:

P564 Characteristics of patients with chronic obstructive pulmonary disease (COPD) discharged from the emergency department – Improving the care pathway for acute exacerbations of COPD

Santino Capocci, David Turner, Robert Pinate, Myra Stern, Louise Restrick. Respiratory Medicine, Whittington Hospital NHS Trust, London, United Kingdom

Introduction: This study characterized COPD-patients attending an Emergency Department (ED) who are discharged.

Methods: Retrospective records-review of COPD-patients discharged from ED (04/2009-03/2010) included demographics, symptoms, spirometry, treatment (pre-ED discharge), ED attendances/hospital admissions & deaths in the subsequent 90 days.

Results: 49/53 episodes coded COPD-ED-discharges in 45 patients were compatible with AECOPD (11% of total 387 AECOPD presentations). 30/49 presented outside 9-5, Monday–Friday. Obstructive spirometry was recorded for 28/45: mean (SD) FEV1 1.21 (0.55)litres. Patients on GP-COPD registers included 2 with restrictive spirometry; 2 had no spirometry; 11 a new COPD diagnosis. Symptoms were increased breathlessness (42/45), cough (38/45) & changing sputum (15/45). Mean (range) symptom duration was 4 (0-28)days (n=40), but ≤1 day in 21/40. 8/46 started corticosteroids and 10/46 antibiotics before attending ED. At discharge 19/49 received/recovered corticosteroids; 16/49 antibiotics. 2 patients died. 15/49 episodes resulted in hospital admission within 90 days, 6/15 within 2 weeks.

Conclusions: Patients discharged from ED with AECOPD account for 11% of COPD presentations (<1 week). >50% presented within 24h of symptoms, 60% outside working-hours. In >20%, diagnosis was not confirmed by spirometry. Only 20% started exacerbation treatment before attending; 30% not given corticosteroids on discharge. Readmission rates were high despite moderately severe COPD. Optimal management of ED-COPD discharges should include corticosteroids, followed by GP-review within 7 days.

P565 Impact of pneumonia on mortality and length of stay in patients hospitalized with acute COPD exacerbations

Siw Lillevik Andreassen 1, Erik Dyb Liuren 2, Nikolai Stenfors 3, Anne Hildeg Hansense 1, 4, 5, 6. The Medical Faculty, Norwegian University of Science and Technology, Trondheim, Norway; 2Department of Internal Medicine, Aalesund Hospital, Aalesund, Norway; 3Department of Respiratory Medicine and Allergy, Östfold Hospital, Östfold, Sweden; 4Pulmonary Medicine, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; 5Department of Pulmonary Medicine, Trondheim University Hospital, Trondheim, Norway; 6Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway

Background and aims: Community acquired pneumonia (CAP) is common among patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (COPD). The aims were to study the impact of (CAP) on the length of hospital stay (LOS), the in-hospital mortality, and the use of non-invasive ventilation (NIV) regardless of COPD severity in patients hospitalized because of COPD exacerbations.

Methods: Retrospectively all COPD hospitalizations in the Departments of Interstitial and Respiratory Medicine in one Swedish and two Norwegian hospitals were registered. A total of 1144 admissions (731 patients) were identified from patient administrative systems. CAP was defined as pneumonia infiltrates on x-ray and CRP values over or equal to 40 mg/L, and 237 admissions followed these criteria. Non-CAP was defined as no pneumonia infiltrates on x-ray and CRP lower than 40.

Results: Patients with CAP had higher usage of NIV (18.3% versus 12.5%, p=0.04) and increased LOS (median 9 days versus 5 days, p<0.001). A higher percentage of those with mild to moderate COPD had CAP compared to those with severe disease (40.0% versus 27.6%, p=0.007). The mortality was not increased in the CAP group.

Conclusions: In conclusion, the in-hospital mortality was not increased among COPD patients with CAP compared to the non-CAP group. This may in part be explained by the more frequent treatment with antibiotics and NIV among the COPD patients with CAP and partly because a higher proportion of those with CAP had mild to moderate COPD compared to the non-CAP group.

P566 Infectious factors influences on cytomorphological picture of bronchial biopsies at COPD exacerbation

Ekaterina Bukreeva 1, Gulnara Seitova 2, Raisa Pleshko 3, 4. Therapy, Siberian Medical University, Tomsk, Russian Federation; 5Medical Genetics, Siberian Medical University, Tomsk, Russian Federation; 6Morphology, Siberian Medical University, Tomsk, Russian Federation

Purpose: To match and analyze bronchial biopsies in dependence on infectious factor at COPD exacerbation.

Material: 46 COPD patients were examined, infectious nature of exacerbation was confirmed at 30 patients. In common group patients in-tracheal lymphocytes count in biopsy was: 29.5±3.4/mm3, intraepithelial eosinophiles–2.3±0.7/mm3, intraepithelial neutrophiles–0.6/mm3, stroma neutrophiles 5.4±1.4/mm3, stromal eosinophiles 9.6±2.6/mm3, squamous cell metaplasia expressiveness–0.5±0.3 point, reserved cell hyperplasia 0.6±0.2 point, goblet cell hyperplasia–0.3±0.1 point.

Endobronchial biopsies and morphometrical estimation of biopsy were made.

Intratinal lymphocytes counts–28.2±4.4/mm3 and 31.2±5.3/mm3; intraepithelial eosinophiles count–2.4±0.7/mm3 and 2.2±0.6/mm3, stromal neutrophiles count–5.2±0.8/mm3 and 5.6±0.9/mm3 were the same in dependent on exacerbation etiology and the same expressiveness of goblet cell hyperplasia.

At noninfectional COPD exacerbation lymphocytes count was 12.3±1.5/mm3 vs 7.6±1.5/mm3 (p<0.05) at infectious COPD exacerbation, although at second group the expressiveness of reserve cell hyperplasia was high than at first group 0.8±0.2/point and 0.4±0.1/point accordingly (p<0.05), and the expressiveness of squamous metaplasia was the same–0.7±0.2/point and 0.3±0.1/point (p<0.05) accordingly. Etiology of COPD exacerbation influences on phtomorphometrical process in bronchial mucosa. This results in more expressive- ness of squamous metaplasia and reserve cell hyperplasia in presence of infectious factor at COPD exacerbation patients.

P567 Cognitive decline in stable and exacerbating COPD vs. controls

James W. Dodd1, Rebecca van Chariton1, Martin van den Broek2, Paul W. Jones1. 1Clinical Sciences, St George’s University of London, London, United Kingdom; 2Department of Neuropsychology, St George’s NHS Healthcare Trust, London, United Kingdom

Background: Poor cognitive function does not mean that decline has occurred. This is the first study in COPD to test for the presence of cognitive decline using formal neuropsychological assessment.

Methods: Neuropsychological tests were performed in stable COPD patients (COPD_S n=50), patients hospitalized with an acute exacerbation (COPD_E n=50) and controls (CTRL_S n=50). Pre-morbid cognition was estimated from adult reading ability, which is resistant to cognitive decline. Performances significantly below predicted ability (p<0.05) are judged to have declined.

Results: The two COPD groups were similar in age, gender and pack yrs, but COPD_E had lower FEV1 and PaO2. Frequency of decline in working memory was not significantly different between the three groups (Table 1). More exacerbations

<table>
<thead>
<tr>
<th>COPD_E</th>
<th>COPD_S</th>
<th>CTRL_S</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>71±11</td>
<td>69±8</td>
<td>64±6</td>
</tr>
<tr>
<td>Gender</td>
<td>11F</td>
<td>27F</td>
<td>11F</td>
</tr>
<tr>
<td>Pack Yrs</td>
<td>61±40</td>
<td>57±24</td>
<td>7±12</td>
</tr>
<tr>
<td>FEV1 (nL)</td>
<td>40±15</td>
<td>52±22</td>
<td>0.03</td>
</tr>
<tr>
<td>PaO2</td>
<td>8±1±6</td>
<td>10.2±1±3</td>
<td>0.05</td>
</tr>
<tr>
<td>PaCO2</td>
<td>5±3±0</td>
<td>5±3±0</td>
<td>0.5</td>
</tr>
<tr>
<td>Time in Processing Speed</td>
<td>35±5%</td>
<td>24±5%</td>
<td>0.001</td>
</tr>
<tr>
<td>Decline in Working Memory</td>
<td>10%</td>
<td>20%</td>
<td>25%</td>
</tr>
</tbody>
</table>

*Group difference (i) p<0.05; between groups p<0.005 (ii). Visited Chiesi at Stand D.30
bating patients showed decline in processing speed than stable patients or controls (p < 0.01) (figure).

Conclusion: Over half of patients prior to discharge with exacerbation and a quarter of stable patients with COPD exhibited significant cognitive decline in processing speed. It is unclear if the decline was acute, chronic or reversible.

P568
Post discharge mortality in North Indian patients with exacerbation of COPD
Hilal Dar1, Umam Khan2, Parvaz Kohi3. Internal & Pulmonary Medicine, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, J&K, India

Background: Mortality rates at 2 years following discharge among patients with exacerbation of COPD have ranged from 22% to 49%. No mortality data is available for such patients from India, especially Kashmir, where COPD is common.

Objective: To determine the post discharge mortality rate and its determinants among patients with COPD hospitalized for acute exacerbation, in a 650-bedded tertiary care facility in Srinagar, Kashmir (India).

Methods: One hundred and fifty-one patients admitted with a diagnosis of acute exacerbation of COPD from October 2008 to October 2010 & discharged after treatment were followed prospectively for a period of 2 years for any deaths and recurrences of exacerbations. The relationship of mortality with potential patient factors was analysed statistically by employing multiple logistic regression analysis, Kaplan-Meier survival analysis and Cox regression.

Results: During a followup of two years following discharge, 39.7% patients died with the majority (34.4%) of deaths occurring during the first year. Risk factors associated with increased mortality included lower health status at discharge (SGRQ score < 60, p value < 0.001), GOLD stage 4 (p < 0.001), BMI < 18 kg/m² (p value < 0.001), SaO₂ < 90% at discharge (p < 0.001) and 6MWT distance of < 150 metres (p < 0.001). Frequency of exacerbations increased with increasing GOLD stage (p < 0.001).

Conclusion: Mortality after discharge is high among north Indian patients admitted with acute exacerbation. Poor functional status at discharge and advanced lung disease are predictive of excessive mortality. Advanced stage of lung disease is associated with frequent exacerbations.

P569
CURB-65 and mortality in pneumonic and non-pneumonic exacerbations of COPD
John Steer1, G. John Gibson2, Stephen C. Bourke1. 1Department of Respiratory Medicine, North Tyneside General Hospital, North Shields, Tyne and Wear, United Kingdom; 2Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, Tyne and Wear, United Kingdom

Background: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) requiring hospitalisation are often complicated by consolidation. In patients with pneumonia and AECOPD (pAECOPD) the CURB-65 prediction tool is widely used yet its utility in this population is uncertain.

Objective: To assess the effect of pneumonia on outcome, and the utility of CURB-65, in AECOPD.

Method: Patients hospitalised with AECOPD were recruited prospectively, with clinical data and CURB-65 collected on admission. Pneumonia was defined as the presence of new consolidation visible radiographically.

Results: Of 920 patients recruited, 299 (32.5%) had complicating pneumonia. In 206 patients with pneumonia and AECOPD (pAECOPD) the CURB-65 prediction tool is widely used yet its utility in this population is uncertain.

Conclusion: Anemia is frequent in COPD patients with exacerbation. Survival is clearly influenced by anemia. Age, iron levels, creatinin levels and META index index influence the most.

P571
Our experience of procalcitonin assay in identifying bacterial COPD exacerbations
Christopher Gough1, Parthipan Pillai1, Rohinton Mulla2. 1Department of Respiratory Medicine, Luton and Dunstable Hospital NHS Foundation Trust, Luton, United Kingdom; 2Department of Microbiology, Luton and Dunstable Hospital NHS Foundation Trust, Luton, United Kingdom

Background: Procalcitonin (PCT) is a pre-hormone which is released in bacterial infection.

Aim of study: To evaluate the benefit of measuring PCT level in recognising bacterial from non bacterial COPD exacerbations.

Method: We prospectively evaluated 24 COPD patients who were admitted with an exacerbation. They had PCT, C-reactive protein (CRP), white blood cell (WBC) measurements and a chest radiograph (CXR). Use of antibiotics were recorded.

Results: 6 patients had CXR findings of consolidation and 5 of them had high PCT indicating bacterial infection. 1 patient had a moderately elevated PCT which could be due to early sampling. In 18 patients who had normal CXR findings, 3 had positive PCT and of these, 1 had high CRP and WBC indicating true bacterial infection. 1 had high CRP with normal WBC which could be due to atypical bacterial infection. 1 had normal CRP with high WBC which could be due to spuriously low PCT result. In 15 patients who had negative PCT, 7 had normal CRP and WBC indicating no bacterial infection. 2 of them had normal CRP but slightly raised WBC and we feel the raised WBC were due to preceding steroid treatment. 3 of them had raised CRP and normal WBC and 3 had both raised CRP and WBC. These may be due to bacterial infection, and the negative PCT represented early sampling. All patients had antibiotics on admission.

Conclusion: In pAECOPD, risk of death is significantly greater than npAECOPD, and is higher than predicted by CURB-65. CURB-65 is a good less predictor of inhospital mortality in pAECOPD than previously reported in CAP; and other prediction tools may be required for this population.
Conclusion: Many patients with COPD exacerbation are treated with antibiotics without bacterial infection. High PCT level indicates bacterial infection in these patients. The converse is also true but this should be used in conjunction with CRP and WBC levels. When normal PCT level is associated with either raised CRP or WBC, a second late PCT level should be measured.

P572
Profile of patients hospitalized with COPD acute exacerbation in respiratory department in Tunisia
Hela Kamoun, Ines Zendah, Ibtihel Khouaja, Samar Sakka, Amel Khattab, Leila Bayahi, Habib Ghedira. Respiratory Department I, Abderrahmen Mami Hospital, Ariana, Tunisia

In developing countries, Respiratory departments are facing new challenges with the huge increase in the number of patients hospitalized with COPD acute exacerbations with limits in ICU beds availability and delay in the management. The aim of this study is to outline the profile of patients with COPD exacerbation hospitalized in a respiratory department in Tunisia.

Methods: One hundred and one files of male patients, randomly selected among whom hospitalized in a Respiratory male department in Tunisia (Tunisia) during the last 20 years for acute COPD exacerbation, are analyzed.

Results: The patients, aged 65 years-old [IC95%: 63-67], are heavy smokers with cigarette consumption of 57 PAX [IC95%: 51-64] and 50% have comorbidities and 15% have a history of myocardial ischemia. Two periods of increased hospitalization are observed: December-January and March-April. Acute respiratory failure with a PaO2<60mmHg is observed in 90% of these patients and Hypercarbia in 15%. Pneumonia is diagnosed in 30% of these patients and bacteria is revealed in 12% mainly Haemophilus Influenzae (9%). Oxygenotherapy is required in 75% of patients and Non Invasive Ventilation (NIV) in 25%, used during the last 5 years. Two patients died during hospitalization and the duration of hospital stay is 17 days [IC95%: 14-19].

Conclusion: High prevalence of acute respiratory failure and Hypercarbia is observed in patients hospitalized with COPD acute exacerbations in respiratory departments in Tunisia with a long duration of hospital stay.

P573
Anemia in COPD patients in Spain: A systematic review
Jesus Díez-Manglano1, Jose Barquero-Romero2,3. Internal Medicine, Hospital Royo Villanova, Zaragoza, Spain; 2Internal Medicine, Hospital Tierra de Barros, Almendralejo, Badajoz, Spain

Objective: To determine the prevalence of anemia in COPD patients in Spain and the consequences of it.

Material and methods: We have conducted an electronic search in PubMed and Embase, a hand-made search of the main Spanish journals of COPD (Archivos de Bronconeumología, Revista Clínica Española and Medicina Clinica) and its references and a hand-made search from 2005 to 2010 of proceedings of annual congresses of European Respiratory Society, Spanish Society of Respiratory Pathology (SEPAR) and Spanish Society of Internal Medicine.

Results: We have obtained 11 studies, 2 journal papers and 9 congress abstracts. 7 studies were conducted in Internal Medicine departments, 3 in Pneumology departments and one in both. All studies used spirometric criteria for COPD diagnose. Six studies defined anemia with WHO criteria and there was significant heterogeneity in exclusion criteria. The studies included 1669 patients, with a mean age of 74.4 years and 537 (32.2%) had anemia. Patients of Internal Medicine departments were older (75.8 vs 70.7 years) There was no difference in prevalence by study department (Pneumology 30.2%, Internal Medicine 32.8%; p=0.32) but prevalence was lower with different of WHO diagnose criteria (24.5% vs 34.9%, p=0.001). Anemia was not associated with readmission or mortality after three months in one study but there was association with readmission in the next year in one study and with one year-mortality in two studies. In one study anemia was associated with mortality during a median follow up of 531 days.

Conclusion: A third of Spanish patients with COPD had anemia. Anemia is associated with more long-term readmissions and mortality.

P574
Interleukin-6, but not pentraxin 3, predicts adverse clinical outcomes on short-term prognosis of patients with incipient heart failure
Pieria Boschetto1, Barbara Bottuzzi2, Alessandro Fucili1, Alfredo Potena2, Licia Ballesteri2, Mariarita Stendardo1, Simonetta Piva3, Alessia Verdutti1, Bianca Bieghel4, Alberto Mantovani4, Leonardo Fabris2, Roberto Ferrari2, Claudio Ceconi1. 1Department of Clinical and Experimental Medicine, University of Ferrara, Ferrara, Italy; 2Research Laboratory Immunology & Inflammation, Instituto Clinico Humanitas, IRCCS, Milano, Italy; 3Respiratory-Physio-Pathology Unit, Hospital-University of Ferrara, Ferrara, Italy; 4Department of Respiratory Diseases, University of Modena & Reggio Emilia, Modena, Italy; 2Department of Translational Medicine, University of Milan, Milano, Italy

We investigated the clinical significance of plasma interleukin (IL)-6, IL-1, IL-1 decoy receptor and pentraxin 3 (PTX3) levels in chronic heart failure (CHF) patients with or without chronic obstructive pulmonary disease (COPD). Plasma levels of these inflammatory markers were measured by using a sandwich enzyme-linked immunosorbent assay in 118 patients. Subjects were ≥65 years, ≥10 pack-years, with a new diagnosis of CHF. The prevalence of COPD was 30% (36/118). Only 2/118 patients had previously diagnosed COPD. The percent of patients given β-blockers (80% vs 89%, P = 0.1), and the optimized to CHF target dose of β-blockers (46.3% vs 59.7%, P = 0.1) were no different in patients with or without COPD. Subjects were prospectively followed for 357 (336-364) days with the end point of death or all-cause hospitalization (adverse event). Baseline plasma levels of IL-6, IL-1, IL-1 decoy receptor and PTX3 were comparable between CHF patients with and without COPD. None of the inflammatory markers correlated with CHF severity. Death or hospitalization occurred in 70 (59.3%) patients. High IL-6 levels was a significant independent predictor for adverse event (WALD CHI-SQUARE P=0.0083), whereas IL-1, IL-1 decoy receptor and PTX3 were not. IL-6 levels correlated positively with high sensitive C-reactive protein (hs-CRP) levels (r = 0.67, p < 0.0001), although hs-CRP was not associated with death or hospitalization.

These results suggest that plasma levels of IL-6 might serve as a prognostic markers in short-term prognosis of elderly CHF patients either with or without COPD.